Peptide Cp40

<strong>Peptide Cp40 </strong>_x000D_ <strong>Catalog number:</strong> B2019223_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> RT_x000D_ <strong>Keywords:</strong> peptide 14_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Rodr√≠guez-Dom√≠nguez MC, Montes-de-Oca-Jim√©nez R, V√°zquez-Chagoy√°n JC, Rivadeneira-Barreiro PE, Zambrano-Rodr√≠guez PC, Ruiz-Riva-Palacio ME, Guti√©rrez-Castillo ADC, de-Castro-Soares S, Vieyra-Reyes P, Arteaga-Troncoso G. Bioinformatic Approach of B and T Cell Epitopes of PLD and CP40 Proteins of Corynebacterium pseudotuberculosis ovis Mexican Isolate 2J-L towards a Peptide-Based Vaccine Int J Mol Sci. 2023 Dec 23;25(1):270._x000D_ 2: Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, Tektonidou M, Konstantinidis T, Papagoras C, Mitroulis I, Germanidis G, Lambris JD, Ritis K. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis J Clin Invest. 2020 Nov 2;130(11):6151-6157._x000D_ 3: Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, Foukas PG, Resuello RRG, Tuplano JV, Kukis D, Tarantal AF, Young AJ, Kajikawa T, Soulika AM, Mastellos DC, Yancopoulou D, Biglarnia AR, Huber-Lang M, Hajishengallis G, Nilsson B, Lambris JD. Safety profile after prolonged C3 inhibition Clin Immunol. 2018 Dec;197:96-106._x000D_ 4: Dai L, Chen Y, Wu J, He Z, Zhang Y, Zhang W, Xie Y, Zeng H, Zhong X. A novel complement C3 inhibitor CP40-KK protects against experimental pulmonary arterial hypertension via an inflammasome NLRP3 associated pathway J Transl Med. 2024 Feb 16;22(1):164._x000D_ 5: Barral TD, Kalil MA, Mariutti RB, Arni RK, Gismene C, Sousa FS, Collares T, Seixas FK, Borsuk S, Estrela-Lima A, Azevedo V, Meyer R, Portela RW. Immunoprophylactic properties of the Corynebacterium pseudotuberculosis-derived MBP:PLD:CP40 fusion protein Appl Microbiol Biotechnol. 2022 Dec;106(24):8035-8051._x000D_ 6: Zhang Y, Shao D, Ricklin D, Hilkin BM, Nester CM, Lambris JD, Smith RJ. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy Immunobiology. 2015 Aug;220(8):993-8._x000D_ 7: Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P, Lin Z, Pascariello C, Raia M, Sica M, Del Vecchio L, Pane F, Lupu F, Notaro R, Resuello RR, DeAngelis RA, Lambris JD. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria Blood. 2014 Mar 27;123(13):2094-101._x000D_ 8: Reis ES, DeAngelis RA, Chen H, Resuello RR, Ricklin D, Lambris JD. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters Immunobiology. 2015 Apr;220(4):476-82._x000D_ 9: Hajishengallis G, Kajikawa T, Hajishengallis E, Maekawa T, Reis ES, Mastellos DC, Yancopoulou D, Hasturk H, Lambris JD. Complement-Dependent Mechanisms and Interventions in Periodontal Disease Front Immunol. 2019 Mar 12;10:406._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/36127336">10: Lamers C, Xue X, Smie≈°ko M, van Son H, Wagner B, Berger N, Sfyroera G, Gros P, Lambris JD, Ricklin D. Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors Nat Commun. 2022 Sep 20;13(1):5519. </a>_x000D_ _x000D_ <strong>Products Related to Peptide Cp40 can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>